

Resource Summary Report

Generated by [dkNET](#) on Sep 2, 2026

NCI-H660

RRID:CVCL_1576

Type: Cell Line

Proper Citation

RRID:CVCL_1576

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1576

Proper Citation: RRID:CVCL_1576

Description: Cell line NCI-H660 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Prostate small cell carcinoma

Defining Citation: [PMID:1563005](#), [PMID:2569043](#), [PMID:2985257](#), [PMID:8806092](#), [PMID:8806103](#), [PMID:11030152](#), [PMID:11304728](#), [PMID:14518029](#), [PMID:15643172](#), [PMID:17401460](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:23671654](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27247353](#), [PMID:27397505](#), [PMID:28766886](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:32586373](#), [PMID:35839778](#)

Comments: Caution: Was originally published as originating from a small cell lung carcinoma (PubMed=2985257), but was later shown to originate from a prostate small cell carcinoma (PubMed=2569043)., Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H660

Synonyms: H660, H-660, NCIH660, NCI660

Cross References: BTO:BTO_0001970, CLO:CLO_0008102, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-5813, BioSample:SAMN03473052, BioSample:SAMN10988121, cancercellines:CVCL_1576,

Cell_Model_Passport:SIDM01123, Cosmic:877360, Cosmic:1021869, Cosmic:1043331, Cosmic:1075272, Cosmic:1689713, Cosmic:2651769, Cosmic:2669168, Cosmic-CLP:1330975, DepMap:ACH-000177, EGA:EGAS00001000978, GEO:GSM482672, GEO:GSM648822, GEO:GSM887440, GEO:GSM888520, GEO:GSM1670256, GEO:GSM1887911, GEO:GSM1887993, IARC_TP53:21084, IARC_TP53:21725, IGRhCellID:NCIH660, LiGeA:CCL_659, PharmacDB:NCIH660_1126_2019, PRIDE:PXD030304, Progenetix:CVCL_1576, Wikidata:Q54908097

ID: CVCL_1576

Record Creation Time: 20220427T220840+0000

Record Last Update: 20260829T234734+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H660.

No alerts have been found for NCI-H660.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 22 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Cao Y, et al. (2026) Targeting the ferritinophagy-lysosome axis as a therapeutic vulnerability in gastroenteropancreatic neuroendocrine tumors. Cell reports. Medicine, 7(4), 102695.

Subramani E, et al. (2026) Targeting arginine metabolism overcomes chemotherapy resistance in aggressive-variant prostate cancers. iScience, 29(6), 116184.

Ji Y, et al. (2026) Serotonin Modulates Lineage Plasticity in Neuroendocrine Prostate Cancer via Epigenetic Reprogramming. Cancer discovery, 16(4), 760.

Derderian S, et al. (2025) Clinical significance of stratifying prostate cancer patients through specific circulating genes. Molecular oncology, 19(5), 1310.

Kumaraswamy A, et al. (2025) LSD1+8a is an RNA biomarker of neuroendocrine prostate cancer. Neoplasia (New York, N.Y.), 63, 101151.

Ku SY, et al. (2025) Preclinical activity of the DLL3-targeted T cell engager MK-6070 in neuroendocrine prostate cancer. Molecular cancer therapeutics.

Zhang D, et al. (2024) Discovery of a peptide proteolysis-targeting chimera (PROTAC) drug of p300 for prostate cancer therapy. *EBioMedicine*, 105, 105212.

Liu S, et al. (2024) UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas. *Cell reports. Medicine*, 5(2), 101381.

Sulsenti R, et al. (2024) Intracellular Osteopontin Promotes the Release of TNF α by Mast Cells to Restrain Neuroendocrine Prostate Cancer. *Cancer immunology research*, 12(9), 1147.

Manzar N, et al. (2024) An integrative proteomics approach identifies tyrosine kinase KIT as a therapeutic target for SPINK1-positive prostate cancer. *iScience*, 27(3), 108794.

Awad D, et al. (2024) Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity. *Cancer research*, 84(5), 703.

Wang Z, et al. (2024) Molecular subtypes of neuroendocrine carcinomas: A cross-tissue classification framework based on five transcriptional regulators. *Cancer cell*, 42(6), 1106.

Wang J, et al. (2024) Cholinergic signaling via muscarinic M1 receptor confers resistance to docetaxel in prostate cancer. *Cell reports. Medicine*, 5(2), 101388.

Yang C, et al. (2023) Induction of PARP7 Creates a Vulnerability for Growth Inhibition by RBN2397 in Prostate Cancer Cells. *Cancer research communications*, 3(4), 592.

Drazdauskienė U, et al. (2023) Fusion sequencing via terminator-assisted synthesis (FTAS-seq) identifies TMPRSS2 fusion partners in prostate cancer. *Molecular oncology*, 17(6), 993.

Zhang A, et al. (2023) Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers. *Cancer research communications*, 3(11), 2358.

Al-Nakouzi N, et al. (2022) Reformation of the chondroitin sulfate glycocalyx enables progression of AR-independent prostate cancer. *Nature communications*, 13(1), 4760.

Yu L, et al. (2022) Increased Expression and Altered Cellular Localization of Fibroblast Growth Factor Receptor-Like 1 (FGFRL1) Are Associated with Prostate Cancer Progression. *Cancers*, 14(2).

Pearson JD, et al. (2021) Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity. *Cancer cell*, 39(8), 1115.

Reina-Campos M, et al. (2019) Increased Serine and One-Carbon Pathway Metabolism by PKC δ Deficiency Promotes Neuroendocrine Prostate Cancer. *Cancer cell*, 35(3), 385.